Monday, July 27, 2015

Study shows dramatic shift to prostate cancer treatments that match risk

CANCER DIGEST – July 27, 2015 – In the first study to document updated treatment trends, researchers found that from 2010 to 2013, 40 percent of men with low-risk prostate cancer opted for active surveillance, in which the disease is monitored closely with blood tests, imaging studies and biopsies. Treatment is deferred unless these tests show evidence of progression.

That is much higher than the 10 percent of low-risk prostate cancer patients who pursued active surveillance in the years from 1990 through 2009. Rates for radiation therapy for this low-risk group have also slipped since 1995. The analysis was based on an ongoing study called, Cancer of the Prostate Strategic Urologic Research Endeavor or CaPSURE Registry. The study published in the July 7, 2015 JAMA.

Monday, July 20, 2015

T-cell therapy slows plasma cancer

The micrograph shows abundant
cancerous plasma cells. – by Nephron
via Wikimedia
CANCER DIGEST – July 20, 2015 – Results from a clinical trial testing a new therapy for multiple myeloma  demonstrated a clinical response in 80 percent of patients with advanced disease who had undergone a stem cell transplants. A clinical response indicates a therapeutic effect for the treatment that uses a person's own immune system to recognize and destroy cancer cells.

Monday, July 13, 2015

Blood test for cancer? Maybe

Dr. Diana Bianchi
CANCER DIGEST – July 13, 2015 – Genetic tests for abnormal chromosomes associated with Downs syndrome and other defects in the fetus, may also detect underlying conditions in the mother, including cancer according to a new study. 

The study reports on the accidental findings from a case series of eight women who had abnormal noninvasive prenatal testing results. While their fetuses had normal chromosomes, later genetic analysis showed that the abnormal findings were due to a variety of undiagnosed cancers in the mothers.

Wednesday, July 8, 2015

Study shows dramatic shift in prostate cancer treatment

CANCER DIGEST – July 8, 2015 – A new analysis of national prostate cancer treatment trends shows that there has been a big shift away from aggressive treatment to watchful waiting and active surveillance for men diagnosed with prostate cancer since the early 1990s.

Watchful waiting avoids aggressive testing and watches for any physical symptoms of progressive disease. It is generally reserved for avoiding treatment altogether for older, sicker patients who will most likely die from something else. Active surveillance uses repeated PSA testing and prostate biopsies to monitor for development of more aggressive disease in younger, healthier patients who might benefit from delaying treatment.